Health

390 bookmarks
Custom sorting
Hiding unhealthy heart outcomes in a low-fat diet trial: the Women's Health Initiative Randomized Controlled Dietary Modification Trial finds that postmenopausal women with established coronary heart disease were at increased risk of an adverse outcome if they consumed a low-fat 'heart-healthy' diet
Hiding unhealthy heart outcomes in a low-fat diet trial: the Women's Health Initiative Randomized Controlled Dietary Modification Trial finds that postmenopausal women with established coronary heart disease were at increased risk of an adverse outcome if they consumed a low-fat 'heart-healthy' diet
The Women's Health Initiative Randomized Controlled Dietary Modification Trial (WHIRCDMT) was designed to test whether the US Department of Agriculture's 1977 Dietary Guidelines for Americans protects against coronary heart disease (CHD) and other chronic diseases. The only significant finding in the original 2006 WHIRCDMT publication was that postmenopausal women with CHD randomised to a low-fat 'heart-healthy' diet in 1993 were at 26% greater risk of developing additional CHD events compared with women with CHD eating the control diet. A 2017 WHIRCDMT publication includes data for an additional 5 years of follow-up. It finds that CHD risk in this subgroup of postmenopausal women had increased further to 47%-61%. The authors present three post-hoc rationalisations to explain why this finding is 'inadmissible': (1) only women in this subgroup were less likely to adhere to the prescribed dietary intervention; (2) their failure to follow the intervention diet increased their CHD risk; and (3) only these women were more likely to not have received cholesterol-lowering drugs. These rationalisations appear spurious. Rather these findings are better explained as a direct consequence of postmenopausal women with features of insulin resistance (IR) eating a low-fat high-carbohydrate diet for 13 years. All the worst clinical features of IR, including type 2 diabetes mellitus (T2DM) in some, can be 'reversed' by the prescription of a high-fat low-carbohydrate diet. The Women's Health Study has recently reported that T2DM (10.71-fold increased risk) and other markers of IR including metabolic syndrome (6.09-fold increased risk) were the most powerful predictors of future CHD development in women; blood low-density lipoprotein-cholesterol concentration was a poor predictor (1.38-fold increased risk). These studies challenge the prescription of the low-fat high-carbohydrate heart-healthy diet, at least in postmenopausal women with IR, especially T2DM. According to the medical principle of 'first do no harm', this practice is now shown to be not evidence-based, making it scientifically unjustifiable, perhaps unethical. Keywords: coronary artery disease; diabetes mellitus; epidemiology; risk factors.
·pubmed.ncbi.nlm.nih.gov·
Hiding unhealthy heart outcomes in a low-fat diet trial: the Women's Health Initiative Randomized Controlled Dietary Modification Trial finds that postmenopausal women with established coronary heart disease were at increased risk of an adverse outcome if they consumed a low-fat 'heart-healthy' diet
An Update on Omega-3 Polyunsaturated Fatty Acids and Cardiovascular Health
An Update on Omega-3 Polyunsaturated Fatty Acids and Cardiovascular Health
Interest in the potential cardiovascular (CV) benefits of omega-3 polyunsaturated fatty acids (Ω-3) began in the 1940s and was amplified by a subsequent landmark trial showing reduced CV disease (CVD) risk following acute myocardial infarction. Since that time, however, much controversy has circulated due to discordant results among several studies and even meta-analyses. Then, in 2018, three more large, randomized trials were released—these too with discordant findings regarding the overall benefits of Ω-3 therapy. Interestingly, the trial that used a higher dose (4 g/day highly purified eicosapentaenoic acid (EPA)) found a remarkable, statistically significant reduction in CVD events. It was proposed that insufficient Ω-3 dosing (1 g/day EPA and docosahexaenoic acid (DHA)), as well as patients aggressively treated with multiple other effective medical therapies, may explain the conflicting results of Ω-3 therapy in controlled trials. We have thus reviewed the current evidence regarding Ω-3 and CV health, put forth potential reasoning for discrepant results in the literature, highlighted critical concepts such as measuring blood levels of Ω-3 with a dedicated Ω-3 index and addressed current recommendations as suggested by health care professional societies and recent significant scientific data. Keywords: omega 3 polyunsaturated fatty acid, omega 3 index, cardiovascular disease
4. The Critical Importance of Dosage There is mounting evidence that higher doses of Ω-3 interventions appear more likely to demonstrate CVD and other clinical benefits. Deficiencies of many nutrients can lead to debilitating and life-threatening chronic disease, which can be corrected with repletion of the deficient nutrient. Supplementation, on the other hand, does not have as profound an effect in people who are nutrient replete. For example, administration of thiamin in wet Beri-Beri can be curative and life-saving [24], whereas supplementation in patients with normal thiamin levels would not be so dramatic. Likewise, studies such as VITAL have shown the most CVD benefit in patients with the lowest baseline levels of Ω-3 [16], who may represent the ideal population for this therapy. High-dose Ω-3 appeared to be beneficial in multiple studies, in addition to the results produced by REDUCE-IT. OMEGA-REMODEL found that 4 g/day Ω-3 (EPA + DHA) for 6 months after acute MI demonstrated a reduction in adverse left ventricular remodeling, non-infarct myocardial fibrosis and serum biomarkers of systemic inflammation beyond the current guideline-based standard of care [25]. Further, the finding that Ω-3 EPA + DHA levels >1.5 g/day are typically required for a clinically meaningful change in TG levels further explains the inconsistent results in trials using lower doses (e.g., 1 g/day) [18]. Goodfellow et al. [26]. Administered Ω-3 of EPA + DHA at 4 g/day and measured endothelial function at baseline and after 4 months of therapy, finding a significant improvement in arterial flow-mediated dilation along with significant TG reduction whereas placebo led to no change in either parameter. Heart transplant patients who received 4 g/day Ω-3 versus placebo as prophylaxis against cyclosporine-induced hypertension demonstrated a systolic blood pressure reduction of 2 +/− 4 mm Hg in the Ω-3 group versus an increase in 17 +/− 4 mm Hg in the placebo group, with a diastolic increase of 10 +/− 3 mm Hg and 21 +/− 2 mm Hg in the treatment and placebo groups, respectively, following 6 months of treatment [27]. The authors concluded that Ω-3 supplementation at 4 g/day (EPA + DHA) was effective for prophylaxis against cyclosporine induced hypertension, which occurs in a high proportion of patients following heart transplantation [28]. In summary, the populations of Japan and Italy in the JELIS and GISSI-P trials, respectively, who demonstrated significant CVD benefits with lower-dose (1–2 g/day) Ω-3 EPA + DHA may have demonstrated such due to a “threshold level” which reaches the therapeutic window of Ω-3. This can explain why higher doses (e.g., 4 g/day) may be required to demonstrate CV benefit, particularly in studies of American populations with lower baseline Ω-3 levels. Figure 3 demonstrates a hypothetical Ω-3 threshold effect with supplement doses of 1 g/day and 4 g/day of EPA + DHA. While GISSI-P originally showed CVD protective effects with an Ω-3 formulation of EPA + DHA, REDUCE-IT and JELIS showed quite dramatic effects using EPA alone. However, a recent large meta-analysis found no statistical difference between the total EPA or combined EPA + DHA dosage on the effects on MACE [21].
·pmc.ncbi.nlm.nih.gov·
An Update on Omega-3 Polyunsaturated Fatty Acids and Cardiovascular Health
Omega-3 fatty acids: a comprehensive scientific review of their sources, functions and health benefits
Omega-3 fatty acids: a comprehensive scientific review of their sources, functions and health benefits
In recent years, public awareness of healthy diets has significantly increased, leading to a rise in the consumption of nutritional supplements. Among these, omega-3 fatty acids have become particularly popular. n − 3 polyunsaturated fatty acids (PUFAs) are widely distributed in marine and terrestrial environments. The primary sources of marine n − 3 fatty acid supplements are oily fish, such as anchovies, sardines and mackerel. Recently, they have drawn considerable attention for their potential therapeutic benefits in treating a range of illnesses, including cancer, neurological disorders, cardiovascular diseases, immunological and reproductive diseases, respectively.
·fjps.springeropen.com·
Omega-3 fatty acids: a comprehensive scientific review of their sources, functions and health benefits
Rote-Hand-Briefe und Informationsbriefe - Rote-Hand-Brief zu Omega-3-Fettsäure-haltigen Arzneimitteln: Dosisabhängig erhöhtes Risiko für Vorhofflimmern bei Patienten mit etablierten kardiovaskulären Erkrankungen oder kardiovaskulären Risikofaktoren
Rote-Hand-Briefe und Informationsbriefe - Rote-Hand-Brief zu Omega-3-Fettsäure-haltigen Arzneimitteln: Dosisabhängig erhöhtes Risiko für Vorhofflimmern bei Patienten mit etablierten kardiovaskulären Erkrankungen oder kardiovaskulären Risikofaktoren
Die Zulassungsinhaber von Omega-3-Fettsäure-haltigen Arzneimitteln informieren darüber, dass systematische Übersichten und Metaanalysen randomisierter kontrollierter Studien ein dosisabhängiges erhöhtes Risiko für Vorhofflimmern zeigen.
·bfarm.de·
Rote-Hand-Briefe und Informationsbriefe - Rote-Hand-Brief zu Omega-3-Fettsäure-haltigen Arzneimitteln: Dosisabhängig erhöhtes Risiko für Vorhofflimmern bei Patienten mit etablierten kardiovaskulären Erkrankungen oder kardiovaskulären Risikofaktoren
Verwirrung um die Wirkung von Omega-3-Fettsäuren
Verwirrung um die Wirkung von Omega-3-Fettsäuren
Background Confusion reigns about omega‑3 fatty acids and their effects. Scientific investigations did not appear to clarify the issue. Guidelines and regulatory authorities contradict each other. Objective This article provides clarity by considering not intake but levels of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in erythrocytes as a percentage of all fatty acids measured (omega‑3 index). Current data The largest database of all methods of fatty acid analyses has been generated with the standardized HS-Omega‑3 Index® (Omegametrix, Martinsried, Deutschland). The omega‑3 index assesses the in EPA+DHA status of a person, has a minimum of 2%, a maximum of 20%, and is optimal between 8% and 11%. In many western countries but not in Japan or South Korea, mean levels are suboptimal. Suboptimal levels correlate with increased total mortality, sudden cardiac death, fatal and non-fatal myocardial infarction, other cardiovascular diseases, cognitive impairment, major depression, premature birth and other health issues. Interventional studies on surrogate and intermediary parameters demonstrated many positive effects, correlating with the omega‑3 index when measured. Due to issues in methodology that became apparent from the perspective of the omega‑3 index many, even large interventional trials with clinical endpoints were not positive, which is reflected in pertinent meta-analyses. In contrast, interventional trials without issues in methodology the clinical endpoints mentioned were reduced. Conclusion All humans have levels of EPA+DHA that if methodologically correctly assessed in erythrocytes, are optimal between 8% and 11%. Deficits can cause serious health issues that can be prevented by optimal levels.
·link.springer.com·
Verwirrung um die Wirkung von Omega-3-Fettsäuren
A single-dose of oral nattokinase potentiates thrombolysis and anti-coagulation profiles
A single-dose of oral nattokinase potentiates thrombolysis and anti-coagulation profiles
Our aim was to determine the quantitative effects of a single-dose of Nattokinase (NK) administration on coagulation/fibrinolysis parameters comprehensively in healthy male subjects. A double-blind, placebo-controlled cross-over NK intervention study was carried out in 12 healthy young males. Following the baseline blood draw, each subject was randomized to receive either a single-dose of 2,000 FU NK (NSK-SD, Japan Bio Science Laboratory Co., Ltd) or placebo with subsequent cross-over of the groups. Subjects donated blood samples at 2, 4, 6 and 8 hours following administration for analysis of coagulation/fibrinolysis parameters. As a result, D-dimer concentrations at 6, and 8 hours, and blood fibrin/fibrinogen degradation products at 4 hours after NK administration elevated significantly (p  0.05, respectively). Factor VIII activity declined at 4 and 6 hours (p  0.05, respectively), blood antithrombin concentration was higher at 2 and 4 hours (p  0.05, respectively), and the activated partial thromboplastin time prolonged significantly at 2 and 4 hours following NK administration (p  0.05 and p  0.01, respectively). All the changes, however, were within the normal range. In conclusion, thus, a single-dose of NK administration appears enhancing fibrinolysis and anti-coagulation via several different pathways simultaneously.
·pmc.ncbi.nlm.nih.gov·
A single-dose of oral nattokinase potentiates thrombolysis and anti-coagulation profiles
A randomized, double-blind, positive-controlled, prospective, dose-response clinical study to evaluate the efficacy and tolerability of an aqueous extract of Terminalia bellerica in lowering uric acid and creatinine levels in chronic kidney disease subjects with hyperuricemia
A randomized, double-blind, positive-controlled, prospective, dose-response clinical study to evaluate the efficacy and tolerability of an aqueous extract of Terminalia bellerica in lowering uric acid and creatinine levels in chronic kidney disease subjects with hyperuricemia
Hyperuricemia is an independent risk factor in chronic kidney disease (CKD). Allopurinol and febuxostat are prescription medicines used to treat hyperuricemia but suffer side-effects. Earlier clinical study has shown that an aqueous extract of Terminalia bellerica (TBE), significantly reduced uric acid levels with no serious adverse effects in hyperuricemic subjects. The objective of this study is to determine the efficacy and tolerability of TB in reducing uric acid and creatinine levels in CKD subjects. Methods: 59-subjects were randomized to three groups-40 mg-once-daily febuxostat, 500 mg-twice-daily and 1000 mg-twice-daily of TBE. Serum uric acid, creatinine levels and estimated-glometular-filtration-rate were measured at baseline, 4, 8, 12, 16, 20, 24-weeks. Biomarkers of oxidative-stress, endothelial function, systemic inflammation, and platelet-aggregation were evaluated at baseline, 4, 8, 12, 24-weeks. Adverse drug reactions were recorded. Statistical analysis evaluated using GraphPadPrism4. Results: 55-subjects completed 24-week study. Starting at 4-weeks, all treatment groups showed a significant decrease in serum uric acid levels from baseline (p ≤ 0.0001). At 24-weeks, febuxostat, T.bellerica 500 mg-twice-daily, and T.bellerica 1000 mg-twice-daily doses decreased mean-percentage serum uric acid by 63.70 ± 4.62, 19.84 ± 6.43 and 33.88% ± 4.95% respectively (p ≤ 0.0001). Significant decrease in serum creatinine with all the groups starting at 16-weeks was seen (p ≤ 0.005-p ≤ 0.0001). At 24-weeks, the mean-percentage change in creatinine levels was 23.71 ± 12.50, 11.70 ± 9.0, and 24.42 ± 8.14, respectively with febuxostat, T.bellerica 500 mg-twice-daily and T.bellerica 1000 mg-twice-daily. Statistically significant (p ≤ 0.05) increase in estimated glomerular filtration rate-(eGFR) was seen at 20 (p ≤ 0.05) and 24-weeks (p ≤ 0.01) for both febuxostat vs T.bellerica 500 mg-twice-daily and T.bellerica 1000 mg-twice-daily vs T.bellerica 500 mg-twice-daily. There was no statistically significant difference between febuxostat and T.bellerica 1000 mg-twice-daily, with an increase of eGFR of 41.38 and 40.39 ml/min/1.73m2 respectively, with the inference that T.bellerica at 1000 mg-twice-daily dose is as good as febuxostat 40 mg-once-daily. Positive improvements were made by all the groups in endothelial function and the related biomarkers and high-sensitivity C-reactive protein. None of the products showed effect on platelet aggregation. Conclusion: In this 24-week study Febuxostat 40 mg, T. bellerica 500 mg-twice-daily and 1000 mg-twice-daily, significantly decreased the serum uric acid and creatinine levels, increased eGFR in CKD subjects. T. bellerica 500 mg-twice-daily and 1000 mg-twice-daily were one-third and more than half as effective at 24-weeks, respectively. T. bellerica extract may be considered a natural alternative for reducing serum uric acid levels. Keywords: Serum creatinine; Terminalia bellerica; Uric acid; eGFR.
·pubmed.ncbi.nlm.nih.gov·
A randomized, double-blind, positive-controlled, prospective, dose-response clinical study to evaluate the efficacy and tolerability of an aqueous extract of Terminalia bellerica in lowering uric acid and creatinine levels in chronic kidney disease subjects with hyperuricemia
Recent insights into luteolin and its biological and pharmacological activities
Recent insights into luteolin and its biological and pharmacological activities
LUT exerts a range of beneficial effects on human health, with the following being reported in many studies: antiallergic, anti-inflammatory, antidiabetic, neuroprotective, and anticancer. Due to their chemical nature, LUT and its glycosides also display antioxidant properties, scavenging free radicals derived from oxidation and chelating metal ions (Cai et al., 1997[3]; Choi et al., 2007[8]; Muruganathan et al., 2022[33]). In recent years, LUT has attracted much attention from the pharmaceutical, food, and cosmetic industries for its plethora of biological and pharmacological activities. Herein, we present a summary of recent key studies performed to evaluate the biological and pharmacological activities of LUT
·pmc.ncbi.nlm.nih.gov·
Recent insights into luteolin and its biological and pharmacological activities
Myo-inositol supplementation improves cardiometabolic factors, anthropometric measures, and liver function in obese patients with non-alcoholic fatty liver disease
Myo-inositol supplementation improves cardiometabolic factors, anthropometric measures, and liver function in obese patients with non-alcoholic fatty liver disease
Non-alcoholic fatty liver disease (NAFLD) as the hepatic manifestation of metabolic syndrome is closely associated with type 2 diabetes mellitus. Myo-inositol (MI)—a 6-C sugar alcohol—with insulin-mimetic, anti-diabetic, lipid-lowering, and anti-inflammatory properties has exerted favorable effects on insulin resistance-related disorders and metabolic disease, while recent animal studies revealed its positive effects on liver function. This study aimed to investigate the effects of MI supplementation on cardiometabolic factors, anthropometric measures, and liver function in obese patients with NAFLD. Methods This double-blinded placebo-controlled randomized clinical trial was carried out on 48 obese patients with NAFLD who were randomly assigned to either MI (4g/day) or placebo (maltodextrin 4g/day) along with dietary recommendations for 8 weeks. Glycemic indices, lipid profile, liver enzymes anthropometric measures, and blood pressure were evaluated pre- and post-intervention. Dietary intakes were assessed using a 3-day 24 h recall and analyzed by Nutritionist IV software. Insulin resistance was estimated using the homeostasis model assessment of insulin resistance (HOMA-IR), and beta-cell function (HOMA-B) was also estimated. Results Anthropometric measures decreased significantly in both groups, while the reduction in weight (p = 0.049) and systolic blood pressure (p = 0.006) in the MI group was significantly greater than in the placebo group after adjusting for baseline values and energy intake. Although energy and macronutrient intakes decreased significantly in both groups, between-group differences were not significant after adjusting for the potential confounders. MI supplementation led to a significant reduction in serum fasting insulin (p = 0.008) and HOMA-IR (p = 0.046). There were significant improvements in lipid profile, liver enzymes, and aspartate aminotransferase/alanine aminotransferase ratio as well as serum ferritin level in the MI group, compared to the placebo group at the endpoint. By MI supplementation for eight weeks, 1 in 3 patients reduced one- grade in the severity of NAFLD. Conclusion MI supplementation could significantly improve IR, lipid profile, and liver function in patients with NAFLD. Further clinical trials with larger sample sizes, longer duration, different MI doses, and other inositol derivatives are recommended. Keywords: anthropometric measures, glycemic indices, lipid profile, myo-inositol, non-alcoholic fatty liver disease, NAFLD, obesity
·pmc.ncbi.nlm.nih.gov·
Myo-inositol supplementation improves cardiometabolic factors, anthropometric measures, and liver function in obese patients with non-alcoholic fatty liver disease
Omega-3 intake is associated with liver disease protection
Omega-3 intake is associated with liver disease protection
Non-alcoholic fatty liver disease (NAFLD) and alcoholic liver disease are among the most common liver diseases worldwide, and there are currently no Food and Drug Administration (FDA)-approved treatments. Recent studies have focused on lifestyle changes to prevent and treat NAFLD. Omega-3 supplementation is associated with improved outcomes in patients with chronic liver disease. However, it is unclear whether Omega-3 supplementation can prevent the development of liver disease, particularly in individuals at an increased (genetic) risk. Methods In this UK Biobank cohort study, we established a multivariate cox proportional hazards model for the risk of incident liver disease during an 11 year follow up time. We adjusted the model for diabetes, prevalent cardiovascular disorders, socioeconomic status, diet, alcohol consumption, physical activity, medication intake (insulin, biguanides, statins and aspirin), and baseline characteristics. Results Omega-3 supplementation reduced the risk of incident liver disease (HR = 0.716; 95% CI: 0.639, 0.802; p = 7.6 × 10−9). This protective association was particularly evident for alcoholic liver disease (HR = 0.559; 95% CI: 0.347, 0.833; p = 4.3 × 10−3), liver failure (HR = 0.548; 95% CI: 0.343, 0.875; p = 1.2 × 10−2), and non-alcoholic liver disease (HR = 0.784; 95% CI: 0.650, 0.944; p = 1.0 × 10−2). Interestingly, we were able to replicate the association with reduced risk of NAFLD in a subset with liver MRIs (HR = 0.846; 95% CI: 0.777, 0.921; p = 1.1 × 10−4). In particular, women benefited from Omega-3 supplementation as well as heterozygous allele carriers of the liver-damaging variant PNPLA3 rs738409. Conclusions Omega-3 supplementation may reduce the incidence of liver disease. Our study highlights the potential of personalized treatment strategies for individuals at risk of metabolic liver disease. Further evaluation in clinical trials is warranted before Omega-3 can be recommended for the prevention of liver disease. Keywords: Omega-3 fatty acids, NAFLD, liver disease, primary prevention, alcoholic liver disease (ALD)
·pmc.ncbi.nlm.nih.gov·
Omega-3 intake is associated with liver disease protection
Berberine: A Review of its Pharmacokinetics Properties and Therapeutic Potentials in Diverse Vascular Diseases
Berberine: A Review of its Pharmacokinetics Properties and Therapeutic Potentials in Diverse Vascular Diseases
Traditional Chinese medicine plays a significant role in the treatment of various diseases and has attracted increasing attention for clinical applications. Vascular diseases affecting vasculature in the heart, cerebrovascular disease, ...
·pmc.ncbi.nlm.nih.gov·
Berberine: A Review of its Pharmacokinetics Properties and Therapeutic Potentials in Diverse Vascular Diseases
Therapeutic Effects of Berberine on Liver Fibrosis are associated With Lipid Metabolism and Intestinal Flora
Therapeutic Effects of Berberine on Liver Fibrosis are associated With Lipid Metabolism and Intestinal Flora
Liver cirrhosis is a form of liver fibrosis resulting from chronic hepatitis caused by various liver diseases, such as viral hepatitis, alcoholic liver damage, nonalcoholic steatohepatitis, autoimmune liver disease, and by parasitic diseases such as ...
·pmc.ncbi.nlm.nih.gov·
Therapeutic Effects of Berberine on Liver Fibrosis are associated With Lipid Metabolism and Intestinal Flora
New SARS-CoV-2 Variants Still Spread Through the Air but Each Has a Unique Strategy to Stay Contagious - Thailand Medical News
New SARS-CoV-2 Variants Still Spread Through the Air but Each Has a Unique Strategy to Stay Contagious - Thailand Medical News
Medical News: Scientists from Imperial College London, The Pirbright Institute, and the MRC-University of Glasgow Centre for Virus Research have uncovered how different SARS-CoV-2 variants have managed to keep spreading through the air despite evolving mutations. Their study used a hamster model to analyze the airborne transmission abilities of both pre-Omicron and Omicron subvariants—sheddi...
·thailandmedical.news·
New SARS-CoV-2 Variants Still Spread Through the Air but Each Has a Unique Strategy to Stay Contagious - Thailand Medical News
A Comprehensive Insight into the Effect of Berberine on Nonalcoholic Fatty Liver Disease (NAFLD): A Systematic Review
A Comprehensive Insight into the Effect of Berberine on Nonalcoholic Fatty Liver Disease (NAFLD): A Systematic Review
Hepatic dysfunction is primarily caused by nonalcoholic fatty liver disease (NAFLD). Recently, berberine (BBR) has attracted researchers’ interest with its hepatic protective property. A systematic r...
·onlinelibrary.wiley.com·
A Comprehensive Insight into the Effect of Berberine on Nonalcoholic Fatty Liver Disease (NAFLD): A Systematic Review
The Therapeutic Effect of Berberine in the Treatment of Nonalcoholic Fatty Liver Disease: A Meta-Analysis
The Therapeutic Effect of Berberine in the Treatment of Nonalcoholic Fatty Liver Disease: A Meta-Analysis
Aim. To assess the efficacy of berberine in the treatment of nonalcoholic fatty liver disease through meta-analysis. Method. We searched Embase, Pubmed, Cochrane Library, and so forth, until March 2016 for randomized controlled trials using ...
·pmc.ncbi.nlm.nih.gov·
The Therapeutic Effect of Berberine in the Treatment of Nonalcoholic Fatty Liver Disease: A Meta-Analysis
The short-term effects of berberine in the liver: Narrow margins between benefits and toxicity
The short-term effects of berberine in the liver: Narrow margins between benefits and toxicity
Berberine is a plant alkaloid to which antihyperglycemic properties have been attributed. It is also known as an inhibitor of mitochondrial functions. In this work short-term translation of the latter effects on hepatic metabolism were investigated using the isolated perfused rat liver. Once-through perfusion with a buffered saline solution was done. At low portal concentrations berberine modified several metabolic pathways. It inhibited hepatic gluconeogenesis, increased glycolysis, inhibited ammonia detoxification, increased the cytosolic NADH/NAD+ ratio and diminished the ATP levels. Respiration of intact mitochondria was impaired as well as the mitochondrial pyruvate carboxylation activity. These results can be regarded as evidence that the direct inhibitory effects of berberine on gluconeogenesis, mediated by both energy metabolism and pyruvate carboxylation inhibition, represent most likely a significant contribution to its clinical efficacy as an antihyperglycemic agent. However, safety concerns also arise because all effects occur at similar concentrations and there is a narrow margin between the expected benefits and toxicity. Even mild inhibition of gluconeogenesis is accompanied by diminutions in oxygen uptake and ammonia detoxification and increases in the NADH/NAD+ ratio. All combined, desired and undesired effects could well in the end represent a deleterious combination of events leading to disruption of cellular homeostasis. Keywords: Alkaloid; Ammonia detoxification; Energy metabolism; Gluconeogenesis; Glycolysis.
·pubmed.ncbi.nlm.nih.gov·
The short-term effects of berberine in the liver: Narrow margins between benefits and toxicity
Administration of phosphatidylcholine increases brain acetylcholine concentration and improves memory in mice with dementia
Administration of phosphatidylcholine increases brain acetylcholine concentration and improves memory in mice with dementia
Studies on the effect of phosphatidylcholine administration on memory are limited. We administered egg phosphatidylcholine to mice with dementia and to normal mice and compared the differences in memory and serum choline concentration, and choline and acetylcholine concentrations and choline acetyltransferase activities of three forebrain regions (cortex, hippocampus and the remaining forebrain). Mice with dementia were produced by mating sibling mice who had impaired memory for 20 generations. These mice had poor memory and low brain acetylcholine concentration. We administered 100 mg of egg phosphatidylcholine (phosphatidylcholine group) or water (control group) by gavage to each mouse daily for about 45 d. Control mice with dementia had poorer memory in passive avoidance performance and lower brain choline (cortex and hippocampus) and acetylcholine (hippocampus and forebrain excluding cortex and hippocampus) concentrations and lower cortex choline acetyltransferase activity than the control normal mice (P 0.05). The administration of phosphatidylcholine to mice with dementia improved memory and generally increased brain choline and acetylcholine concentrations to or above the levels of the control normal mice. In normal mice, phosphatidylcholine treatment did not affect memory or acetylcholine concentrations in spite of the great increase in choline concentrations in the three brain regions. Serum choline concentration in mice treated with phosphatidylcholine increased to a similar level in both strains of mice, indicating that the absorption of phosphatidylcholine was not impaired in mice with dementia. The results suggest that administration of egg phosphatidylcholine to mice with dementia increases brain acetylcholine concentration and improves memory.
·pubmed.ncbi.nlm.nih.gov·
Administration of phosphatidylcholine increases brain acetylcholine concentration and improves memory in mice with dementia
The Role of Uric Acid in Human Health: Insights from the Uricase Gene
The Role of Uric Acid in Human Health: Insights from the Uricase Gene
Uric acid is the final product of purine metabolism and is converted to allantoin in most mammals via the uricase enzyme. The accumulation of loss of function mutations in the uricase gene rendered hominoids (apes and humans) to have higher urate concentrations compared to other mammals. The loss of human uricase activity may have allowed humans to survive environmental stressors, evolution bottlenecks, and life-threatening pathogens. While high urate levels may contribute to developing gout and cardiometabolic disorders such as hypertension and insulin resistance, low urate levels may increase the risk for neurodegenerative diseases. The double-edged sword effect of uric acid has resurrected a growing interest in urate’s antioxidant role and the uricase enzyme’s role in modulating the risk of obesity. Characterizing both the effect of uric acid levels and the uricase enzyme in different animal models may provide new insights into the potential therapeutic benefits of uric acid and novel uricase-based therapy. Keywords: neurodegenerative diseases, cardiovascular diseases, fructose metabolism, adaptation, evolutionary biology, genomics, gout, hyperuricemia
·pmc.ncbi.nlm.nih.gov·
The Role of Uric Acid in Human Health: Insights from the Uricase Gene
Associations of dietary choline intake and kidney function with hyperuricemia in Chinese children and adolescents: a cross-sectional study
Associations of dietary choline intake and kidney function with hyperuricemia in Chinese children and adolescents: a cross-sectional study
Limited studies have suggested an effect of dietary choline intake on uric acid levels. We aim to investigate the associations between choline intake …
·sciencedirect.com·
Associations of dietary choline intake and kidney function with hyperuricemia in Chinese children and adolescents: a cross-sectional study
Choline: An Essential Nutrient for Skeletal Muscle
Choline: An Essential Nutrient for Skeletal Muscle
Background: Choline is an essential micronutrient with a pivotal role in several metabolic pathways contributing to liver, neurological, and hematological homeostasis. Although choline is commonly administered to improve physical performance, its effects on muscle are still unclear. The aim of this scoping review is to analyze the role of choline on skeletal muscle in terms of biological effects and clinical implications. Methods: A technical expert panel (TEP) of 6 medical specialists with expertise in muscle physiology and skeletal muscle disorders performed the review following the PRISMA-ScR (Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews) model. The TEP planned a research on PubMed selecting “choline” as MeSH (Medical Subject Headings) term adding to PubMed Search Builder the terms ”skeletal muscle” and “muscle striated”. TEP considered for eligibility articles published in the last 30 years, including original researches, particularly in vitro studies, and animal and clinical studies in the English language. Results: From the 1239 studies identified, TEP included 14 studies, 3 in vitro, 9 animal, and 2 clinical studies. Conclusions: Our scoping review elucidates and summarizes the crucial role of choline in modulating muscle fat metabolism, muscle proteins homeostasis, and the modulation of inflammation and autophagy. Keywords: choline, skeletal muscle, striated muscle, review, muscle fat, muscle protein, autophagy, inflammation, muscle performance, vitamin B complex
·pmc.ncbi.nlm.nih.gov·
Choline: An Essential Nutrient for Skeletal Muscle